Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Etretinate (Ro 10-9359) 是一种口服芳香族维甲酸,对牛皮癣和其他皮肤病综合征有效。 它激活类视黄醇受体,引起细胞分化的诱导、细胞增殖的抑制和炎症细胞对组织浸润的抑制。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 198 | 现货 | ||
10 mg | ¥ 331 | 现货 | ||
25 mg | ¥ 557 | 现货 | ||
50 mg | ¥ 835 | 现货 | ||
100 mg | ¥ 1,348 | 现货 | ||
200 mg | ¥ 1,990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 198 | 现货 |
产品描述 | Etretinate (Ro 10-9359) is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. It activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells. |
体外活性 | K03861 inhibits CDK2 activity by competing with binding of activating cyclins. [1] |
体内活性 | There is a significant decrease in mean dermal thickness (P < 0.05) and changes in collagen bundles in the etretinate-treated mice group for a 28-day period compared to control groups. TUNEL assay shows that the density of TUNEL-positive cells in the dermis of etretinate-treated mice for a 14-day period is significantly increased (P < 0.05). The ratio of procollagen α 1 (I) chain to β actin mRNA from etretinate-treated mice for a 1-day period decreased significantly compared to that of the control mice, but the ratio from etretinatetreated mice for a 14-day period increased significantly (P < 0.05)[2]. Etretinate reduces dermal thickness, and suppresses the appearance of skin lesions by inducting apoptosis and perhaps regulation of cytokine expression in MRL/lpr mice[3]. |
细胞实验 | The HSC-5 cells are plated in 96-well plates at a density of 1.5×103 per 100 μL and used for experiments. Preliminary experiments are performed to determine the effective dose and cytotoxicity of etretinate. The cells are incubated for 72 h with etretinate at concentrations of 5, 10, 25 and 50 nmol⁄L [dissolved in saline containing 0.0001% dimethyl sulfoxide (DMSO)]. The cells are then incubated for a further 2 h with or without 200 μmol⁄L ALA (Sigma). Each plate is then irradiated using a metal halide lamp at doses of 10, 20, 40 and 80 J⁄cm2 (Only for Reference) |
别名 | Retinoid, Tegison, Etretinato, Ethyl etrinoate, Ro 10-9359, 依曲替酯 |
分子量 | 354.48 |
分子式 | C23H30O3 |
CAS No. | 54350-48-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/mL (183.4 mM)
Ethanol: 65 mg/mL (183.4 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.821 mL | 14.1052 mL | 28.2103 mL | 70.5258 mL |
5 mM | 0.5642 mL | 2.821 mL | 5.6421 mL | 14.1052 mL | |
10 mM | 0.2821 mL | 1.4105 mL | 2.821 mL | 7.0526 mL | |
20 mM | 0.1411 mL | 0.7053 mL | 1.4105 mL | 3.5263 mL | |
50 mM | 0.0564 mL | 0.2821 mL | 0.5642 mL | 1.4105 mL | |
100 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7053 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Etretinate 54350-48-0 Apoptosis Others Retinoid Tegison Inhibitor Etretinato Ethyl etrinoate inhibit Ro 10-9359 依曲替酯 inhibitor